Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry
Abstract Introduction Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patien...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-06-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01456-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849767548239740928 |
|---|---|
| author | April W. Armstrong Steven R. Feldman Timothy Fitzgerald Theodore Alkousakis Adam Sima Alvin Li Hyung-Joo Kang Sandra I. Main Saakshi Khattri Linda Stein Gold |
| author_facet | April W. Armstrong Steven R. Feldman Timothy Fitzgerald Theodore Alkousakis Adam Sima Alvin Li Hyung-Joo Kang Sandra I. Main Saakshi Khattri Linda Stein Gold |
| author_sort | April W. Armstrong |
| collection | DOAJ |
| description | Abstract Introduction Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy. Methods Patients from the CorEvitas Psoriasis Registry initiating biologics between April 2015 and September 2023 were categorized according to low (< 3%), medium (3–10%), or high (> 10%) BSA involvement. Measures assessed at initiation of biologic therapy included health-related quality of life, itch, pain, fatigue, psoriatic arthritis, psoriasis disease characteristics, and medical history. Overlap between BSA groups for each outcome was calculated via non-parametric Mann–Whitney statistic transformation (range 0.0–1.0; 0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]; 0 or 1 indicates complete dissimilarity) to determine whether each measure differed in randomly selected patients with low or medium versus high BSA. Results Of 1640 patients who initiated biologics, 7.0% had low BSA, 46.9% had medium BSA, and 46.2% had high BSA involvement. PRO overlap statistics ranged from 0.52 to 0.59 and from 0.60 to 0.70 for randomly selected patients with high versus medium and low BSA, respectively, indicating patients with high and medium BSA are likely to have similar levels of disease burden, and patients with high BSA are slightly more likely to have higher disease burden than those with low BSA. Near complete overlap (range 0.44–0.58) was observed for psoriasis disease characteristics and medical history in the low versus high and medium BSA groups. Conclusion Observed overlap in PROs across BSA categories shows that patients with low BSA can experience similarly poor quality of life and high symptom burden to those with higher BSA. These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden. Trial Registration ClinicalTrials.gov: NCT02707341. |
| format | Article |
| id | doaj-art-8a14d3013f5f44d3ba4172274bf8a8db |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-8a14d3013f5f44d3ba4172274bf8a8db2025-08-20T03:04:10ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-06-011582117213010.1007/s13555-025-01456-5Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis RegistryApril W. Armstrong0Steven R. Feldman1Timothy Fitzgerald2Theodore Alkousakis3Adam Sima4Alvin Li5Hyung-Joo Kang6Sandra I. Main7Saakshi Khattri8Linda Stein Gold9University of California Los AngelesWake Forest University School of MedicineJohnson & JohnsonJohnson & JohnsonCorEvitas, LLCCorEvitas, LLCCorEvitas, LLCCorEvitas, LLCMount Sinai Medical CenterHenry Ford Health SystemAbstract Introduction Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy. Methods Patients from the CorEvitas Psoriasis Registry initiating biologics between April 2015 and September 2023 were categorized according to low (< 3%), medium (3–10%), or high (> 10%) BSA involvement. Measures assessed at initiation of biologic therapy included health-related quality of life, itch, pain, fatigue, psoriatic arthritis, psoriasis disease characteristics, and medical history. Overlap between BSA groups for each outcome was calculated via non-parametric Mann–Whitney statistic transformation (range 0.0–1.0; 0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]; 0 or 1 indicates complete dissimilarity) to determine whether each measure differed in randomly selected patients with low or medium versus high BSA. Results Of 1640 patients who initiated biologics, 7.0% had low BSA, 46.9% had medium BSA, and 46.2% had high BSA involvement. PRO overlap statistics ranged from 0.52 to 0.59 and from 0.60 to 0.70 for randomly selected patients with high versus medium and low BSA, respectively, indicating patients with high and medium BSA are likely to have similar levels of disease burden, and patients with high BSA are slightly more likely to have higher disease burden than those with low BSA. Near complete overlap (range 0.44–0.58) was observed for psoriasis disease characteristics and medical history in the low versus high and medium BSA groups. Conclusion Observed overlap in PROs across BSA categories shows that patients with low BSA can experience similarly poor quality of life and high symptom burden to those with higher BSA. These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden. Trial Registration ClinicalTrials.gov: NCT02707341.https://doi.org/10.1007/s13555-025-01456-5BiologicsBody surface areaPatient-reported outcomesPsoriasis |
| spellingShingle | April W. Armstrong Steven R. Feldman Timothy Fitzgerald Theodore Alkousakis Adam Sima Alvin Li Hyung-Joo Kang Sandra I. Main Saakshi Khattri Linda Stein Gold Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry Dermatology and Therapy Biologics Body surface area Patient-reported outcomes Psoriasis |
| title | Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry |
| title_full | Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry |
| title_fullStr | Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry |
| title_full_unstemmed | Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry |
| title_short | Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry |
| title_sort | patient reported outcomes by baseline body surface area involvement among individuals initiating biologic therapy results from the corevitas psoriasis registry |
| topic | Biologics Body surface area Patient-reported outcomes Psoriasis |
| url | https://doi.org/10.1007/s13555-025-01456-5 |
| work_keys_str_mv | AT aprilwarmstrong patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT stevenrfeldman patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT timothyfitzgerald patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT theodorealkousakis patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT adamsima patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT alvinli patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT hyungjookang patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT sandraimain patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT saakshikhattri patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry AT lindasteingold patientreportedoutcomesbybaselinebodysurfaceareainvolvementamongindividualsinitiatingbiologictherapyresultsfromthecorevitaspsoriasisregistry |